We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Multiparameter Autoantibody Detection Aids Diagnosis of Myositis

By LabMedica International staff writers
Posted on 12 Jul 2023

Idiopathic inflammatory myopathies (IIM), or myositides, are a collection of systemic autoimmune rheumatic diseases. More...

These disorders are characterized by chronic inflammation of the skeletal muscle, and in some instances, can be linked to cancer. Due to their rarity, resemblance to other rheumatic diseases, and the potential for overlap syndromes, diagnosing IIMs can be complex. Pinpointing the exact subtype of the disease is crucial due to diverse treatment options. Autoantibodies are critical diagnostic biomarkers for IIM and help in identifying disease subtypes. The German Society for Neurology (DGN) issued guidelines in 2022, mandating the identification of myositis-specific autoantibodies (MSA) and myositis-associated autoantibodies (MAA) as a diagnostic step. Given the low prevalence and frequent isolation of IIM autoantibodies, antibody detection must be as comprehensive as possible.

EUROIMMUN (Lübeck, Germany) has developed a line blot (EUROLINE Autoimmune Inflammatory Myopathies 20 Ag Profile) that uniquely combines 20 nuclear and cytoplasmic antigens. This assists in detecting and differentiating autoantibodies in IIM, making it the most comprehensive commercially available line blot for IIM diagnostics. The antigen portfolio encompasses the MSA target antigens Zo, Ks, Ha, cN-1A, OJ, EJ, PL-12, PL-7, SRP, Jo-1, SAE1, NXP2, MDA5, TIF1γ, Mi-2α and Mi-2β and the MAA target antigens Ku, PM-Scl75, PM-Scl100 and Ro-52, each printed onto separate membrane chips for optimal antibody detection efficiency. The immunoblot analysis is particularly effective in identifying autoantibodies against cytoplasmic antigens, which other methods such as indirect immunofluorescence can miss. The assay process and result evaluation can be fully automated.

This specific antibody detection approach aids in diagnosing IIM subforms in light of clinical symptoms. Notably, anti-cN-1A is the sole known serological marker for sporadic inclusion body myositis (sIBM). Since anti-cN-1A is rarely found in other IIMs, its detection can help distinguish sIBM from other IIM forms, aiding in early diagnosis. The EUROLINE is the sole commercial line blot that includes this antigen. The antigens Zo, Ks, and Ha supplement the tRNA synthetase antigen spectrum for differential diagnosis of anti-synthetase syndrome (ASS) along with EJ, OJ, PL-12, PL-7, Jo-1, and SRP. Current research is exploring the link of antibodies against Zo, Ks, and Ha with interstitial lung disease. Autoantibodies against Mi-2α, Mi-2β, NXP2, TIF1γ, SAE1, and MDA5 are indicative of dermatomyositis (DM), with anti-NXP2 and anti-TIF1γ often associated with malignancies. Antibodies against Ku, PM-Scl-75, and PM-Scl100 are typically found in overlap syndromes, while anti-SRP is present in necrotizing myositis. Detecting specific autoantibodies can significantly accelerate diagnosis, enabling prompt therapeutic intervention. Autoantibody profiling also helps in assessing malignancy risk and predicting therapy outcomes.

Related Links:
EUROIMMUN 


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.